SEC INSIDER TRANSACTIONS

THERMO FISHER SCIENTIFIC INC. (TMO) Insider Transactions

Explore official ownership filings, with every record linked to its source.

Reported data · not live

TMO · THERMO FISHER SCIENTIFIC INC.

Filing window SEC codes (comma separated) Security type Order

More transaction filters

Roles: director,officer,ten_percent_owner,otherOwner nameOfficer titleOwnership: D, I, unknownoriginal or amendedTransaction fromTransaction throughFiled fromFiled throughMinimum quantityMaximum quantityMinimum priceMaximum priceMinimum calculated valueMaximum calculated valueResults per page (1–100)

OR within codes/roles; AND between categories. Roles apply to buyers and sellers. Owner predicates match the same owner. Missing values fail numeric/date filters. Value is quantity × reported price for non-derivative rows only; derivative values are unknown. Amendments stay separate; joint owners do not duplicate rows.

Reset filters

Active filters: days=6m

Stale snapshot · Covered: filings 2026-05-14 to 2026-11-13 · 40 filings · fetched 2026-11-13T20:19:33Z

Recent reported activity

0purchase rows on this page

15sale rows on this page

165matching filing rows

Purchases and sales count original non-derivative P and S rows. Awards, gifts, exercises, derivatives and amendments are shown separately and are not described as market purchases.

Transaction / filed	Reporting owner(s)	Code / security	Quantity	Price as filed	Ownership	Source
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	S Sale (market/private)Common Stock · Non-derivative	80D	633.99	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F9	S Sale (market/private)Common Stock · Non-derivative	560D	632.94	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F8	S Sale (market/private)Common Stock · Non-derivative	1,430D	632.01	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F7	S Sale (market/private)Common Stock · Non-derivative	1,035D	630.87	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F6	S Sale (market/private)Common Stock · Non-derivative	1,250D	629.85	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F5	S Sale (market/private)Common Stock · Non-derivative	2,601D	628.82	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F4	S Sale (market/private)Common Stock · Non-derivative	1,314D	627.66	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F3	S Sale (market/private)Common Stock · Non-derivative	821D	626.83	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F2	S Sale (market/private)Common Stock · Non-derivative	909D	625.45	Direct	Form 4 ↗0000097745-26-000152
2026-08-20Filed 2026-08-24	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.80, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13) and (14) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.17 to $627.08, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.33 to $628.29, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.36 to $629.33, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.41 to $630.37, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $630.47 to $631.37, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $631.52 to $632.44, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $632.60 to $633.32, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $625.00 to $625.97, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $626.00 to $626.99, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $627.00 to $627.99, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $628.00 to $628.94, inclusive. F14 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $629.00 to $629.20, inclusive. F15 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F16 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References:	M Exercise / conversionCommon Stock · Non-derivative	10,000A	309.63	Direct	Form 4 ↗0000097745-26-000152
2026-08-19Filed 2026-08-20	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $613.09 to $613.49, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. References:	M Exercise / conversionStock Option (Right to Buy) · Derivative	11,440D	0	Direct	Form 4 ↗0000097745-26-000150
2026-08-19Filed 2026-08-20	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $613.09 to $613.49, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. References: F1	S Sale (market/private)Common Stock · Non-derivative	11,440D	613.12	Direct	Form 4 ↗0000097745-26-000150
2026-08-19Filed 2026-08-20	Britt Lisa P.Officer · Sr. VP and Chief HR Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $613.09 to $613.49, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. References:	M Exercise / conversionCommon Stock · Non-derivative	11,440A	418.32	Direct	Form 4 ↗0000097745-26-000150
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References:	M Exercise / conversionStock Option (Right to Buy) · Derivative	14,300D	0	Direct	Form 4 ↗0000097745-26-000149
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F3	M Exercise / conversionStock Option (Right to Buy) · Derivative	11,200D	0	Direct	Form 4 ↗0000097745-26-000149
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F2	S Sale (market/private)Common Stock · Non-derivative	14,300D	600	Direct	Form 4 ↗0000097745-26-000149
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References:	M Exercise / conversionCommon Stock · Non-derivative	14,300A	418.32	Direct	Form 4 ↗0000097745-26-000149
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F2	S Sale (market/private)Common Stock · Non-derivative	11,200D	600	Direct	Form 4 ↗0000097745-26-000149
2026-08-11Filed 2026-08-13	Shafer Michael DOfficer · Executive Vice President Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 Includes 44.079 shares acquired under the Issuer's employee's stock purchase plan on May 15, 2026. F2 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2025. F3 The options vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1	M Exercise / conversionCommon Stock · Non-derivative	11,200A	309.63	Direct	Form 4 ↗0000097745-26-000149
2026-08-07Filed 2026-08-10	Holmes Joseph R.Officer · VP & Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References: F1	M Exercise / conversionStock Option (Right to Buy) · Derivative	420D	0	Direct	Form 4 ↗0001839832-26-000003
2026-08-07Filed 2026-08-10	Holmes Joseph R.Officer · VP & Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	S Sale (market/private)Common Stock · Non-derivative	420D	584.81	Direct	Form 4 ↗0001839832-26-000003
2026-08-07Filed 2026-08-10	Holmes Joseph R.Officer · VP & Chief Accounting Officer Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The option vested in four equal installments on February 25, 2021, 2022, 2023 and 2024. References:	M Exercise / conversionCommon Stock · Non-derivative	420A	309.63	Direct	Form 4 ↗0001839832-26-000003
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F15	M Exercise / conversionStock Option (Right to Buy) · Derivative	275D	0	Direct	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F9	S Sale (market/private)Common Stock · Non-derivative	117D	593.31	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009
2026-08-07Filed 2026-08-10	CASPER MARC NDirector · Officer · Chairman & CEO Filing context Reported filing row; may be amended. Do not sum filings blindly. F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 27, 2026. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12) and (13) to this Form 4. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $584.01 to $584.93, inclusive. F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.05 to $586.04, inclusive. F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $586.05 to $586.88, inclusive. F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.37 to $587.91, inclusive. F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.21 to $590.06, inclusive. F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.40 to $590.98, inclusive. F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $593.22 to $593.36, inclusive. F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.26 to $579.27, inclusive. F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $580.71 to $580.72, inclusive. F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $581.85 to $581.86, inclusive. F13 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $583.01 to $584.00, inclusive. F14 The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein. F15 The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024. References: F1, F8	S Sale (market/private)Common Stock · Non-derivative	495D	590.78	IndirectBy Floral Park Associates, Inc.	Form 4 ↗0001216055-26-000009

Imported instruments only. Joint owners do not multiply transactions. Amendments are separate filing rows, not additional trades. No aggregate trade totals are implied.